CLNN - Clene Inc.
IEX Last Trade
4.995
-0.050 -1.001%
Share volume: 1,100
Last Updated: Fri 27 Dec 2024 08:30:24 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$5.04
-0.05
-0.99%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
7.63%
1 Month
22.41%
3 Months
5.39%
6 Months
1,272.97%
1 Year
1,853.85%
2 Year
402.97%
Key data
Stock price
$5.00
DAY RANGE
$4.92 - $5.10
52 WEEK RANGE
$0.29 - $6.96
52 WEEK CHANGE
$1,612.74
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Robert D. Etherington
Region: US
Website: clene.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: clene.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Clene Inc. focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis. The company also markets and distributes dietary supplements.
Recent news